top of page

TRANSFAL
SUB-STUDY OF PREDICTIVE BIOMARKERS FOR PALBOCICLIB AND ENDOCRINE THERAPY IN ER+/HER2- ADVANCED BREAST CANCER

BREAST
52
280
Sub-study
Spain, France, Italy, UK, Germany, Czech Republic, Russia
Closing
CLINICAL TRIAL DETAILS
THE TRANSFAL PROJECT IS A SUB-STUDY WITHIN THE PARSIFAL CLINICAL TRIAL. THE INITIAL GOAL WILL BE TO ANALYZE THE MOLECULAR TUMOR PROFILE AT THE TIME OF PROGRESSION IN PATIENTS WITH MODERATE SENSITIVITY TO PALBOCICLIB IN COMBINATION WITH FIRST-LINE ENDOCRINE THERAPY. FOR THIS PURPOSE, DIFFERENT MOLECULAR APPROACHES, SUCH AS DIFFERENTIAL PROTEOMICS, IN VIVO PDX MODELS, FISH, DNA SEQUENCING, WILL BE RUN ON AN INITIAL SUBSET OF THE PARSIFAL POPULATION.
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
PRESS RELEASE
SCIENTIFIC IMPACT
AACR 2024 - PARSIFAL-LONG substudy (transFAL) lay language summary: https://www.medsir.org/_files/ugd/39f166_d48da3cca8194199bcc85264b222e648.pdf | AACR - PARSIFAL-LONG substudy (transFAL) poster: https://static.wixstatic.com/media/39f166_4b3c83a81ffa46d5875ca0818f0052ec~mv2.jpg | ESMO 2020 presentation: https://39f1664e-7766-40bf-9b5a-e3575d54bba6.usrfiles.com/ugd/39f166_692b7adb9de44503892ed00c635b5d69.pdf | SABCS 2019 poster: https://39f1664e-7766-40bf-9b5a-e3575d54bba6.usrfiles.com/ugd/39f166_bcec3ba15b26418f890fbd57fbcb727d.pdf
BLOG ARTICLES RELATED
PHERGAIN SITES
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi AntolÃn
Dr. Escrivá de RomanÃ
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page
